Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies Inc. (NYSE: A) will release its financial results for the second quarter of fiscal year 2022 on May 24, 2022, after market close. A live webcast of the investor conference call will be held on the same day at 1:30 p.m. PT. Agilent, a leader in life sciences and diagnostics, reported $6.32 billion in revenue for fiscal 2021 and has approximately 17,000 employees globally. A replay of the webcast will be available for 90 days on the company’s investor relations website.
Agilent Technologies Inc. (NYSE: A) has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL), reinforcing its commitment to biopharmaceutical innovation. This partnership aims to enhance continuous manufacturing solutions, improve supply chain logistics, and increase accessibility to biotherapeutics. CEO Mike McMullen emphasized the growing importance of innovative measurement tools for delivering life-saving drugs. Agilent's advanced technologies, such as online HPLC sampling and real-time sensors, will play a vital role in shaping future bioprocess development.
Agilent Technologies (NYSE: A) announced advancements in cancer research at the American Association for Cancer Research Annual Meeting in New Orleans from April 8-13, 2022. The company showcased its innovative products like the Agilent Magnis NGS Prep System, allowing rapid assay setups, and the XF Pro Analyzer for live cell monitoring. Agilent's commitment to cancer research aims to support researchers with a comprehensive toolkit for diagnostics and therapeutic development. In fiscal 2021, Agilent generated $6.32 billion in revenue and has a global workforce of 17,000.
Agilent Technologies Inc. (NYSE: A) has received CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx assay. This approval allows use in patients with muscle-invasive urothelial carcinoma (MIUC) who exhibit tumor cell PD-L1 expression ≥ 1%, specifically for adjuvant treatment with OPDIVO® (nivolumab). Urothelial carcinoma poses a significant health burden, with 500,000 new cases globally and a 50% relapse rate in MIUC patients. This development enhances treatment options for high-risk patients and underscores Agilent's commitment to advancing diagnostic solutions.
Agilent Technologies Inc. (NYSE: A) announced expanded CE-IVD marking in the EU for its PD-L1 IHC 28-8 pharmDx, aiding in identifying esophageal squamous cell carcinoma patients for treatment with OPDIVO® (nivolumab) alongside chemotherapy or YERVOY® (ipilimumab). Esophageal cancer, the seventh most common globally, had about 600,000 new cases in 2020. This advancement marks a significant step in providing targeted immunotherapy options, promising improved survival rates for patients.
Agilent Technologies Inc. (NYSE: A) has joined the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), highlighting its commitment to enhancing biopharmaceutical manufacturing processes. This partnership aims to advance analytical tools and solutions critical for biotherapeutics and gene therapy. Senior VP Darlene Solomon emphasized the need for improved biomanufacturing efficiencies. Agilent's innovations in automation, machine learning, and real-time analytics will support these efforts, contributing to lower costs and improved bioprocessing efficiency in the biopharmaceutical sector.
Arima Genomics, Inc. has successfully closed a $7 million Series B Preferred Stock financing round, with participation from both new and existing investors, including Genetron Health and Agilent Technologies. The funds aim to accelerate innovation and expand the company’s capabilities in 3D genomics, which provides crucial insights into the structure of genomes, enhancing research and therapeutic development. Arima's technologies are increasingly recognized in precision oncology, with over 600 global customers and more than 200 peer-reviewed studies leveraging its products.
Agilent Technologies Inc. (NYSE: A) announced Dr. Federica Fiorini as the recipient of the 2022 Darlene Solomon Award, recognizing her research in metabolomics. The award was presented at the iSLS10 symposium in Singapore on March 8-10. Dr. Fiorini will gain exposure through financial support for attending mass spectrometry conferences and working at Agilent's Global Solutions Development Center. The award aims to empower early-career female scientists and promote innovative research in lipidomics. Dr. Fiorini expressed gratitude and enthusiasm for advancing her field.
Edwards, a leader in semiconductor supply, is investing in a new 200,000-square-foot manufacturing facility in Chandler, Arizona. This facility will utilize advanced technologies to support the growing semiconductor market, creating approximately 200 jobs locally. With construction underway, the site will begin operations in Q3, focusing on the remanufacturing and assembly of vacuum pump equipment essential for semiconductor fabrication. This investment underlines Edwards' commitment to sustainable practices and enhancing supply chain capacity in North America.
Agilent Technologies Inc. (NYSE: A) announced that CFO Bob McMahon will participate in Q&A sessions at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 11:10 a.m. EST, and the Barclays Global Health Care Conference on March 16, 2022, at 2:05 p.m. EDT. Both events will be webcast live, with access links available prior to the sessions on Agilent's Investor Relations website. Agilent is a leader in life sciences and diagnostic markets, generating $6.32 billion in revenue in fiscal 2021.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
